FDA reviewing Mallinckrodt's neonatal jaundice candidate

Mallinckrodt plc (NYSE:MNK) said FDA accepted for review an NDA for stannsoporfin to treat neonates at risk for developing severe hyperbilirubinemia, or jaundice. The PDUFA date is Aug. 22...